Abstract:For the majority of pediatric patients with soft tissue tumors, some form of selective systemic therapy is required. Here we show that bone marrow-derived non-hematopoietic mesenchymal stem cells (MSCs) integrate into pediatrics soft tissue sarcoma xenografts as stromal fibroblasts. Importantly, exogenously administered MSC preferentially engraft at the sites of disseminated tumor nodules throughout the body. These findings suggest the development of novel anti-cancer therapies based on the local production of biological agents by gene manipulated MSC. We show that human MSC can be effectively transduced with adenovirus type 5-based vectors and with vectors based on adeno-associated virus (AAV). The majority of AAV serotypes tested (AAV1/6, 2, 3, 4, 5, and 8) are capable of transducing hMSC, albeit with relatively low efficiencies. Vector modifications to the AAV capsid, such as the inclusion of the RGD-tripeptide motif in capsids of either AAV1 or AAV2-based vectors, or modification of the vector genome to generate "double-stranded", or "self-complementary" AAV vectors, both lead to significant increases in AAV-mediated hMSC gene transduction. Here, we examined whether hMSC producing human TNF-related apoptosis inducing ligand (hTRAIL) (hTRAIL-MSC) can inhibit the growth of subcutaneous human Ewing's Sarcoma xenografts in nude mice. MSC were transduced with an hTRAIL expressing adenovirus, or AAV vector. These hTRAIL-MSC produced hTRAIL and could directly induce apoptosis of A673 Ewing's sarcoma cells in co-culture experiments in vitro. When co-injected with A673 sarcoma cells into the flanks of nude mice (1:2 ratio of hMSC to A673 sarcoma cells), all treated animals failed to develop tumors (n=5). Control animals co-injected with eGFP-MSC (Ad-eGFP transduced hMSC) and A673 sarcoma cells (n=5), or A673 sarcoma cells alone (n=10) all developed tumors. We then injected hTRAIL-MSC intravenously (IV) (single dose of 5 105 MSC) into nude mice bearing established subcutaneous A673 tumors; tumor growth was inhibited approximately 30% as compared to untreated controls, and as compared to controls treated with eGFP-MSC (n=5) (p=0.01). Immunohistochemical analysis of hTRAIL-MSC treated animals showed engraftment and differentiation of hMSC into myofibroblast-like tumor-associated stroma cells. IV injected hTRAIL-MSC prolonged the survival of mice bearing A673 Ewing sarcoma grafts as compared to untreated animals, or control (eGFP-MSC) treated animals. These data suggest that IV administered gene-modified MSC can inhibit the growth of pediatric soft tissue sarcomas. Importantly, the antitumor effects were only achieved when MSC were integrated into the tumor microenvironment, but not when MSC were injected subcutaneously into the opposite flank. Therefore, tumor inhibition required spatial proximity of MSC to the malignant cells. These findings suggest that TRAIL can serve as a direct inhibitor of tumor proliferation and suggest the use of gene-manipulated MSC for pediatric cancer therapy.

Triazine-modified Dendrimer for Efficient TRAIL Gene Therapy in Osteosarcoma.

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Allogenic Γδ T Cell and Tumor Cell Fused Vaccine for Enhanced Immunotherapeutic Efficacy of Osteosarcoma

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Antitumor Effect of TRAIL on Oral Squamous Cell Carcinoma using Magnetic Nanoparticle-Mediated Gene Expression

Biodegradable Carbon Dioxide‐Derived Non‐Viral Gene Vectors for Osteosarcoma Gene Therapy

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Plasmid Porf-Htrail Targeting to Glioma Using Transferrin-Modified Polyamidoamine Dendrimer

Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Oncolytic Adenovirus Zd55-Trail As A Therapy Against Cervical Cancer

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Reduction-responsive nucleic acid nanocarrier-mediated miR-22 inhibition of PI3K/AKT pathway for the treatment of patient-derived tumor xenograft osteosarcoma

PLK1shRNA and Doxorubicin Co-Loaded Thermosensitive PLGA-PEG-PLGA Hydrogels for Osteosarcoma Treatment

Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity

Suppressing Orthotopic Pancreatic Tumor Growth With A Fiber-Modified Adenovector Expressing The Trail Gene From The Human Telomerase Reverse Transcriptase Promoter

74. Specific Delivery of hTRAIL and Inhibition of Ewing's Sarcoma Growth by Transplantation of Viral Vector-Transduced Bone Marrow-Derived Mesenchymal Stem Cells (MSC)

Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer

Dual peptide-engineered and gadolinium-doped polydopamine particles as targeted nanotheranostics for the treatment of osteosarcoma and related osteolysis